• April 9, 2020  

    New Pancreatic Cancer Therapies Extending Lives Bookmark

    George Lundberg, MD

    Article from WebMD curated by Editor in Chief George Lundberg, MD, who notes: 

    An aggressive 3-part approach may offer hope for some patients with stage 4 pancreatic cancer.

    Go to full article published by WebMD.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 8, 2020  

    Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer

    Smruti Vidwans, PhD

    In 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »

  • March 16, 2020  

    New Treatments For Bladder Cancer in 2020

    Emma Shtivelman, PhD

    In 2019 and early 2020, the U.S. Food and Drug Administration (FDA) approved a number of new drugs for bladder cancer of all stages, and more treatments are on the horizon. Here’s a snapshot of what’s happening right now in bladder cancer treatment: Non-muscle invasive bladder cancer treatments (NMIBC) In patients with NMIBC, tumors are confined to the inner cell layer of the bladder… Read more »

  • March 9, 2020  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often afflicts children. An investigational drug called ONC201 has shown early promise in some patients whose tumors have a specific genetic mutation called H3 K27M.… Read more »

  • February 22, 2020  

    ‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 22, 2020  

    Data Favor Max Resection for All Glioblastomas Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 31, 2020  

    FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In precision oncology, drugs combinations may provide new effective treatment.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 10, 2020  

    Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients

    Lola Rahib, PhD

    In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »

  • January 7, 2020  

    FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer Bookmark

    George Lundberg, MD

    Article from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.

    Go to full article published by The Cancer Letter.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 26, 2019  

    Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer Bookmark

    George Lundberg, MD

    Article from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes: 

    In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.

    Go to full article published by the National Cancer Institute.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.